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Abstract 
Background: Parkinson disease (PD) is a progressive neurodegenerative disorder presenting with symptoms of 
resting tremor, bradykinesia, rigidity, postural instability and additional severe cognitive impairment over time. These 
symptoms arise from a decrease of available dopamine in the striatum of the brain resulting from the breakdown 
and death of dopaminergic (DA) neurons. A process implicated in the destruction of these neurons is mitochondrial 
breakdown and impairment. Upkeep and repair of mitochondria involves a number of complex and key components 
including Pink1, Parkin, and the PGC family of genes. PGC-1α has been characterized as a regulator of mitochondria 
biogenesis, insulin receptor signalling and energy metabolism, mutation of this gene has been linked to early onset 
forms of PD. The mammalian PGC family consists of three partially redundant genes making the study of full or partial 
loss of function difficult. The sole Drosophila melanogaster homologue of this gene family, spargel (srl), has been 
shown to function in similar pathways of mitochondrial upkeep and biogenesis.
Results: Directed expression of srl-RNAi in the D. melanogaster eye causes abnormal ommatidia and bristle forma-
tion while eye specific expression of srl-EY does not produce the minor rough eye phenotype associated with high 
temperature GMR-Gal4 expression. Ddc-Gal4 mediated tissue specific expression of srl transgene constructs in D. 
melanogaster DA neurons causes altered lifespan and climbing ability. Expression of a srl-RNAi causes an increase in 
mean lifespan but a decrease in overall loco-motor ability while induced expression of srl-EY causes a severe decrease 
in mean lifespan and a decrease in loco-motor ability.
Conclusions: The reduced lifespan and climbing ability associated with a tissue specific expression of srl in DA neu-
rons provides a new model of PD in D. melanogaster which may be used to identify novel therapeutic approaches to 
human disease treatment and prevention.
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Background
Parkinson disease (PD) is a common and progressive 
neurological disease that is estimated to afflict 1  % of 
all individuals over the age of 60  years worldwide [1]. 
Although the direct cause of PD is as of yet unknown, 
the clinical symptoms include resting tremor, bradykin-
esia, rigidity and postural instability. In addition to these 
classical symptoms recent discoveries have shown that 
effects may include cognitive impairment such as loss of 
memory and depression [2]. These symptoms are caused 
by a decrease in the amount of dopamine available in the 
striatum area of the brain and in many cases character-
ized by an accumulation of harmful protein aggregates 
known as Lewy bodies in the neurons of the substantia 
nigra pars compacta [3]. The eventual dysfunction and 
breakdown of these neurons is responsible for the symp-
toms and pathology of PD [4]. Both genetic and environ-
mental factors have been found to contribute to PD with 
many forms of the disease being attributed to a combi-
nation of the two. Environmental factors include: chemi-
cal exposure, brain trauma, obesity, diabetes and age [5]. 
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Alternatively, there have been a number of familial cases 
of PD identified which suggests a genetic link to certain 
forms of this disease [6]. This link is especially strong in 
the case of early onset PD which shows a bias towards 
genetic causes, while environmental conditions seem to 
more often than not be linked to late onset PD [2]. Identi-
fying and analysing the genes responsible for these inher-
ited forms of PD may give rise to mechanisms of disease 
progression that are not presently understood. Impaired 
neuronal activity has been shown to contribute to the 
lack of dopamine commonly associated with PD etiology. 
Identifying the cause of this neuronal impairment may 
help lead to new, effective, strategies to combat PD.
As important and necessary components of eukaryotic 
cells, mitochondria are integral components in the crea-
tion of adenosine tri-phosphate (ATP) for use as chemi-
cal energy and are involved in other important pathways 
such as the control of cellular growth and death, cell sig-
nalling and differentiation [7]. As the mitochondria are 
involved in such diverse and important cellular functions; 
it is not surprising that the breakdown or dysfunction of 
mitochondria may result in a number of disorders or dis-
eases including but not limited to movement disorders 
such as PD [8]. Many of these disorders are caused by 
defective removal of damaged or non-functional mito-
chondria and a subsequent lack of de novo synthesis of 
new mitochondria to replace the aforementioned dam-
aged organelles. Thus, the study of genes that regulate 
and monitor the health of mitochondria is a reasonable 
next step for determining potential disease prevention 
strategies.
The peroxisome proliferation activated co-receptor 
gamma (PCG) family of genes have been linked to mito-
chondrial biogenesis [9]. PGC-1α has been found to be 
involved in de novo mitochondrial synthesis in various 
tissues including the liver and brain [10]. Medical data 
has shown that polymorphisms in PGC-1α have been 
commonly found in patients with early onset and severe 
PD [11]. Other members of this gene family, PGC-1β [12] 
and PRC (PGC-1-related-cofactor) [13] have been shown 
to maintain some functional homology with PGC-1α 
and protein sequence comparison of these genes shows 
close similarity and conservation of active sites [14] mak-
ing it difficult to completely study the loss of function in 
human cells.
PGC-1α shares a functional pathway with two previ-
ously characterised PD genes; PINK1 and Parkin [15]. 
Parkin is a component of a multi-protein E3 ubiquitin 
ligase that leads to the ubiquitination and subsequent 
destruction of cellular proteins [16]. Mutations to the 
Parkin gene result in the degeneration of dopaminergic 
(DA) neurons, most likely by allowing the aggregation of 
multiple dysfunctional mitochondria that eventually lead 
to overall cell death [8]. PINK1 (PTEN induced putative 
kinase 1) is a serine/threonine-protein kinase that acts by 
recruiting Parkin to damaged mitochondria [17]. Simi-
larly to Parkin, mutations in PINK1 lead to degeneration 
and dysfunction of dopaminergic neurons [18]. Parkin 
and PINK1 act together in concert along with mitofu-
sin 2 (Mfn2) to remove any damaged or dysfunctional 
mitochondria that may be present while PGC-1α activ-
ity regulates the creation of new mitochondria to replace 
damaged or removed organelles [19]. Mutation to any 
of the components of this pathway can lead to impaired 
mitochondria, decreased cellular fitness and eventual cell 
death.
A single PGC family gene homologue, spargel (srl), has 
been identified in Drosophila melanogaster. The SRL pro-
tein has been characterized as a downstream component 
of the insulin signalling TOR pathway and srl mutant flies 
have a “lean” phenotype typical of mutations that affect 
growth and proliferation and reduced mitochondrial fit-
ness [20]. Although ubiquitous overexpression of srl has 
been found to negatively impact organism survival, tissue 
specific srl expression has been found to provide benefi-
cial effects. Overexpression of srl has been shown to be 
sufficient to increase mitochondrial activity and medi-
ate tissue specific lifespan extension in the digestive tract 
and intestine [21]. Altered expression of srl in the heart 
has been shown to increase capacity for exercise based 
endurance improvement while decreased srl in cardiac 
muscle decreases the loco-motor and endurance ability of 
flies [22]. The lack of gene redundancy present in D. mel-
anogaster makes it an ideal model system to determine 
the effects of reduced or increase levels of srl expression 
on whole organism and neuronal longevity, leading to a 
new model of PD for use in future therapeutic studies.
Results
A multiple alignment of the SRL protein with the three 
mammalian homologues; PGC-1α, PGC-1β and PRC, 
provides evidence of evolutionarily conserved protein 
structure between the human and D. melanogaster forms 
of this gene (Fig. 1). These proteins differ in length from 
1664 amino acids in the case of PRC to 798 amino acids 
for PGC-1α but functional domains remain consistent 
across all four. Each contains an N terminal proline rich 
domain, a bipartite nuclear localization signal, C terminal 
serine rich region and a highly conserved RNA recogni-
tion motif as well as an arginine rich region in all except 
PGC-1β (Fig. 1). Each of the mammalian proteins contain 
at least one leucine rich motif (LXXLL) known to interact 
with nuclear receptors [23] that is not found in srl, how-
ever, an alternative leucine rich motif (FEALLL) is pre-
sent which has been shown to also interact with nuclear 
receptors and serve the same function in D. melanogaster 
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[24]. The similarities between D. melanogaster and mam-
malian proteins indicate that SRL is an ideal candidate to 
study PGC family activity while avoiding the functional 
redundancy found in other systems.
In order to assay the effect of altered srl activity in neu-
rons, we induced expression of three constructs previ-
ously used by Mukherjee and Duttaroy [25]; srl-RNAi 
(UAS-srlHMS00857), srl-RNAi (UAS-srlHMS00858) and a srl-
EY (UAS- srlEY05931) in the neuron rich D. melanogaster 
eye. Eyes develop two separate yet equally important 
tissues which can be assayed for neuronal loss during 
development; ommatidia and bristles. At 25 and 29  °C 
(the latter for increased expression) under the direction 
of GMR-Gal4, expression of both srl-RNAi transgenes 
decreases the number of ommatidia and bristles present 
in the eye (Fig.  2). Tissue specific expression of srl-EY 
results in a slight decrease in number of ommatidia and 
bristles at 25 °C and an increase in number of ommatidia 
and bristles at 29 °C. Similarly, UAS-lacZ under the con-
trol of GMR-Gal4 shows a slight rough eye phenotype at 
29 °C which is not produced by the expression of srl-EY.
To determine if the phenotype caused by altered srl 
expression found in the eye is conserved in all neurons 
we next looked at tissue specific expression of srl in the 
DA neurons. To assay the effect of altered srl activity 
in DA neurons, we conditionally expressed a srl-RNAi 
transgene (UAS-srlHMS00857) and a tissue specific srl-
EY construct under the control of the Ddc-Gal4 driver. 
Under the control of Ddc-Gal4, srl-RNAi expression 
leads to a marked increase in median lifespan with a pre-
mature loss of climbing ability over time when compared 
to the UAS-lacZ controls (Fig. 3). Tissue specific expres-
sion of srl-EY lead to both a decrease in lifespan and loco-
motor climbing ability under the control of the Ddc-Gal4 
driver. This indicates that altered srl expression responds 
in a tissue specific nature, even within similar cell types 
such as neurons. We obtained somewhat similar results 
when we carried out the experiment at 29 °C, indicating 
that the observed differences in phenotype between eye 
and dopaminergic neurons was tissue and not tempera-
ture specific.
Discussion
PGC-1α has been identified as a modulator of mito-
chondrial biogenesis, energy metabolism [26], insulin 
signalling [27] and is believed to be linked to human ail-
ments including Alzheimer [28], Huntington [29] and 
Parkinson diseases [30]. The study of human PGC-1α 
is complicated by the partial functional redundancy 
of the other PGC family members, PGC-1β and PRC 
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Fig. 1 The PGC mammalian family and the Drosophila melanogaster protein SRL share conserved protein domains. a Aligned sequences show 
the position of each domain in one D. melanogaster and three human PGC family protein sequences. Light upward diagonal indicates proline rich 
region, wide downward diagonal indicates serine rich region, dark vertical indicates RNA recognition region, solid black box indicates nuclear localiza-
tion sequence, black frame indicates arginine rich region, LXXLL and FEALLL indicate leucine rich nuclear recognition motifs. b A multiple alignment 
between PGC-1α, PGC-1β, PRC and SRL shows a high degree of sequence conservation within the RNA recognition motif found at the carboxyl ter-
minus of each protein. Domains were identified using ScanProsite [41], alignment was done using ClustalW2 [42]. Protein sequences obtained from 
UniProt, accession numbers [Uniprot NP_037393 (PGC-1α)], [Uniprot NP_573570 (PGC-1β)], [Uniprot NP_055877 (PRC)] and [Uniprot NP_730835 
(SRL)]. Elements of this figure were adapted from Scarpulla et al. [43]
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(PGC-1-related-cofactor). The single Drosophila PGC 
family homologue, srl, has been linked to mitochondrial 
biogenesis and insulin signalling [25]. We investigate srl 
as a potential key regulator of disease progression and 
seek to model this system for future analysis.
The D. melanogaster eye has been used to study 
potential genes involved in neurodegenerative disease 
due to the neuron rich nature of the developing tissues 
located there. When two srl-RNAi constructs are 
expressed in this tissue, there is a significant reduction 
in the number of ommatidia and bristles formed. This 
effect is exacerbated when flies are raised at 29 °C, caused 
by an increase in the activity of the Gal4 expression 
system. Alternatively, expression of a previously 
characterized srl-EY transgene seems to have little effect 
on ommatidial viability under normal physiological 
conditions (25  °C). At 29  °C the amount of ommatidial 
degeneration increases significantly across all genotypes. 
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Fig. 2 Tissue specific srl expression in the Drosophila melanogaster eye results in a reduction in both ommatidia and bristle number. a Scanning 
electron micrographs of D. melanogaster eyes taken at a horizontal field width of 500 µm. Genotypes are as follows: (I) GMR-Gal4/UAS-lacZ 25 °C, 
(II) GMR-Gal4/srl-RNAi 1 (UAS-srlHMS00857) 25 °C, (III) GMR-Gal4/srl-RNAi 2 (UAS-srlHMS00858) 25 °C, (IV) GMR–Gal4/srl-EY (UAS-srlEY05931) 25 °C, (V) GMR-Gal4/
UAS-lacZ 29 °C, (VI) GMR-Gal4/srl-RNAi 1 (UAS-srlHMS00857) 29 °C, (VII) GMR-Gal4/srl-RNAi 2 (UAS-srlHMS00858) 29 °C, (VIII) GMR–Gal4/srl-EY (UAS-srlEY05931) 
29 °C. Images were taken with a FEI MLA 650. b Flies show a decrease in the mean number of ommatidia present when srl-RNAi 1 (UAS-srlHMS00857) 
and srl-RNAi 2 (UAS-srlHMS00858) are driven with the GMR-Gal4 driver in both standard conditions (25 °C) and at a higher temperature (29 °C). Flies 
show a slight but not significant decrease in ommatidia number when srl-EY is expressed in a tissue specific manner (UAS-srlEY05931) in both standard 
conditions (25 °C) and at a higher temperature (29 °C). c Flies show a strong decrease in bristle number in standard conditions (25 °C) when srl-RNAi 
1 (UAS-srlHMS00857), srl-RNAi 2 (UAS-srlHMS00858) and srl-EY (UAS-srlEY05931) are expressed in D. melanogaster eyes. At a higher temperature (29 °C) srl-EY 
causes an increase in number of bristles formed compared to lacZ controls, however, this is not statistically significant (UAS-lacZ). Comparisons were 
measured using a one-way ANOVA and significance was tested using a Tukey post hoc test, n = 10. *P < 0.05, **P < 0.01, ***P < 0.001
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Interestingly, overexpression of srl-EY at 29  °C does not 
cause significant degeneration of ommatidia or bristles 
as found in the UAS-lacZ control at higher temperatures. 
Experiments by Mukherjee and colleagues have shown 
that srl overexpression can rescue FoxO mediated eye 
destruction, indicating a similar effect [25]. It is possible 
that tissue specific expression of srl in the eye may be 
sufficient to prevent physiological stressors from causing 
aberrant cell formation under these conditions.
Surprisingly, expression of srl-RNAi in DA neu-
rons under the control of the Ddc-Gal4 driver caused 
an increase in the mean lifespan of flies. Despite the 
increased longevity of these flies, they lose their climbing 
ability slightly earlier than controls. When considering 
the increase in lifespan this indicates that although they 
live longer, they may have severe loco-motor defects dur-
ing the latter part of their life. Alternatively, DA expres-
sion of the srl-EY transgene under the control of the 
Ddc-Gal4 driver showed a significant decrease in lifespan 
compared to UAS-lacZ controls. The loco-motor and 
climbing ability of these flies was also decreased. Taken 
together, the premature mortality and decreased climbing 
ability displayed in flies expressing srl-EY in dopamine 
decarboxylase neurons appears to give a new, previously 
uncharacterized, model of PD in D. melanogaster.
Altered srl expression has been found to cause various 
phenotypes in a tissue specific manner. Ubiquitous over-
expression of srl has been shown to moderately reduce 
mean lifespan while overexpression in intestinal stem 
cells and cells of the digestive tract caused increased 
lifespan [21]. Similarly, increased srl expression in car-
diac muscle has been linked to exercise based endur-
ance improvement and cardiovascular performance [22]. 
These findings lead us to believe that altered srl expres-
sion does not react the same way in the eye model of neu-
rodegeneration as in DA neurons.
Although an increase in lifespan caused by the 
expression of srl-RNAi was an unexpected result, we 
hypothesize that a strong decrease in srl expression 
causes an amount of mitochondrial stress sufficient to 
activate a protein stress response which has been shown 
to increase lifespan [31]. The exact mechanism of this 
increase is a topic of much debate with the most popular 
hypothesis involving an activation of the unfolded protein 
response (UPR) [32]. However, it has recently been 
found that in Caenorhabditis elegans many of the genes 
involved in the UPR are non-essential for this increase in 
longevity, suggesting another mechanism for the increase 
in organismal longevity [33]. Alternatively, this increase 
in longevity may involve the concept of stress causing 
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Fig. 3 Tissue specific altered srl expression in dopaminergic neurons 
can lead to a model of Parkinson disease Drosophila melanogaster. a 
Expression of srl-RNAi (UAS-srlHMS00858) driven by Ddc-Gal4 results in 
an increase in lifespan compared to UAS-lacZ controls. Dopaminergic 
srl-EY (UAS-srlEY05931) expression resulted in a decrease in lifespan com-
pared to UAS-lacZ controls. Longevity is shown as a percent survival 
(P < 0.05 as determined by the Mantel-Cox Log Rank test) N ≥ 200. b 
Expression of srl-RNAi (UAS-srlHMS00858) and srl-EY (UAS-srlEY05931) driven 
by Ddc-Gal4 cause a decrease in climbing ability over time. Dopa-
minergic specific expression of srl-EY causes a more severe decrease, 
however, srl-RNAi expressing flies live longer and climb slightly worse 
than UAS-lacZ controls indicating a potential decrease in climbing 
activity compared to lifespan. Climbing ability was determined via 
nonlinear curve fit (CI 95 %). Error bars indicate standard error of the 
mean, n = 50. c Expression of srl-RNAi (UAS-srlHMS00858) driven by 
Ddc-Gal4HL4.3D at 29 °C results in an increase in lifespan while srl-EY 
(UAS- srlEY05931) expression at 29 °C resulted in a decrease in lifespan 
compared to UAS-lacZ controls. Longevity is shown as a percent 
survival (P < 0.0001 as determined by the Mantel-Cox Log Rank test) 
N ≥ 150
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the formation of reactive oxygen species (ROS) at a low 
level which provoke cellular anti-oxidants, causing a 
stronger response to future ROS exposure [34]. The most 
commonly used term for this is mitochondrial hormesis 
(or mitohormesis) [35]. It is quite plausible that stress 
causes increased longevity through a combination of 
factors involving ideas from both of the aforementioned 
explanations.
Conclusion
The use of a model organism in identifying and char-
acterizing the pathways of disease progression is a 
fundamental step in creating new and novel treat-
ment options. Studying the consequences of altered 
srl expression in D. melanogaster allows us to study 
the complex mammalian PGC gene family in a system 
containing only a single homologue. Identifying the 
role of srl will lead to an understanding of the associa-
tions and pathways related to proper function of this 
gene and subsequently the consequences of improper 
gene function. Currently, there is no preventative treat-
ment available for PD with limited options available to 
combat advanced symptoms. Identification of this new 
model of PD provides a framework for more advanced 
studies into complex gene interactions. Connecting cel-
lular processes and characterizing genetic pathways of 
disease progression may eventually allow for the pre-
ventative treatment of genetic forms of PD and novel 
therapeutic options.
Methods
Drosophila media
The standard cornmeal-yeast-molasses-agar medium is 
made with 65 g/L cornmeal, 10 g/L nutritional yeast and 
5.5  g/L agar supplemented with 50  mL/L fancy grade 
molasses and 5 mL of 0.1 g/mL methyl 4-hydroxybenzo-
ate in 95 % ethanol and 2.5 mL of propionic acid in stand-
ard plastic shell vials. The medium is stored at 4–6 °C and 
warmed to room temperature for use.
Drosophila transgenic lines
To express transgenes in a subset of cells, including the 
dopaminergic neurons, the Ddc-Gal4HL4.3D line was the 
generous gift of Dr. Jay Hirsh (University of Virginia) [36]. 
The following lines were obtained from the Bloomington 
Drosophila Stock Center at Indiana University-
Bloomington: (1) to drive expression behind the 
morphogenetic furrow in the developing eye disc Glass 
Multiple Reporter-Gal412 (GMR-Gal4; [37]); (2) to act as 
a benign control for the ectopic expression of transgenes 
UAS-lacZ4−2−1 (UAS-lacZ; [38]); (3) to express in the 
presence of Gal4 the endogenous srl gene product a 
line bearing an EPgy2 insertion in the 5 prime flanking 
region of srl: y w; P{EPgy2srlEY05931 (UAS-srlEY05931) and 
(4) to, in the presence of Gal4, express a dsRNA for RNA 
inhibition (RNAi) of srl: y sc v; P{TRiP.HMS00857}attP2 
(UAS-srlHMS00857) and y sc v; P{TRiP.HMS00858}attP2 
(UAS-srlHMS00858).
Scanning electron microscopy of Drosophila melanogaster 
eye
Female virgins of the GMR-Gal4 were mated with UAS-
lacZ, UAS-srlEY05931, UAS-srlHMS00857 and UAS-srlHMS00858 
males. Male progeny of each cross were collected, aged 
for 3–5  days and frozen at −80  °C. Flies were mounted 
under a dissecting microscope, and desiccated over-
night. The eyes of mounted flies were imaged via scan-
ning electron micrography at 130 times magnification 
with a Mineral Liberation Analyzer 650F scanning elec-
tron microscope. Total bristle count, and total ommatidia 
count were obtained using ImageJ [39].
Ageing analysis
Female virgins of the Ddc-Gal4 line were mated with 
UAS-lacZ, UAS-srlEY05931 and UAS-srlHMS00858 males. 
Male progeny of each cross were collected, maintained in 
cohorts of no more than 20 to avoid crowding and were 
placed on new medium every 2 or 4 days for the duration 
of the experiment. Flies were scored for viability every 
2  days until all flies in all genotypes perished. Survival 
curves were compared by the log-rank (Mantel Cox) test.
Loco‑motor analysis
From each of the crosses described above, fifty male 
progeny were collected and maintained in vials of ten 
flies, and transferred to new medium twice weekly 
throughout the duration of the experiment. One week 
(7  days) after collection, and in seven-day intervals, 
five cohorts of flies for each genotype were assessed for 
climbing ability as previously described [40]. Flies were 
scored every 7  days for their ability to climb within a 
glass tube of 1.5  cm diameter. Ten trials of each cohort 
of ten or less flies were scored based upon two cm inter-
vals of height reached. A climbing index was calculated 
for each vial by the equation: climbing Index = ∑ nm/N, 
where n is the number of flies at a given level, m is the 
score for that level (1–5), and N is the total number of 
flies climbed for that trial. A nonlinear regression curve 
of 95 % confidence intervals was used to analyze graphs 
of 5—climbing index as a function of time in days for 
each genotype. The slope (k) and Y-intercept (Y°) of each 
non-linear regression curve were calculated, where slope 
represents the rate of decline in climbing ability, and the 
Y-intercept represents the initial climbing ability (in the 
form of 5—climbing index). As neither the slope nor the 
Y-intercept remained constant across all groups, it was 
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necessary that both parameters were incorporated into 
statistical analysis to determine differences in climbing 
ability. A comparison of fits concluded whether or not 
curves differed between groups.
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